Cargando…

Risk attitudes and risk perceptions in individuals with multiple sclerosis

BACKGROUND: Little is known about risk attitudes and risk perceptions in multiple sclerosis (MS). OBJECTIVES: The objectives of this paper are to investigate the range of risk attitudes and risk perceptions and examine associations between risk attitudes and risk perceptions and demographic and clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glanz, Bonnie I, Greeke, Emily, LaRussa, Allison, Stuart, Fiona, Rintell, David J, Chitnis, Tanuja, Healy, Brian C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5453630/ https://www.ncbi.nlm.nih.gov/pubmed/28607735 http://dx.doi.org/10.1177/2055217316665406

Ejemplares similares

Evaluation of an Online Platform for Multiple Sclerosis Research: Patient Description, Validation of Severity Scale, and Exploration of BMI Effects on Disease Course
por: Bove, Riley, et al.
Publicado: (2013)

Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2013)

The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis
por: Glanz, Bonnie I, et al.
Publicado: (2021)

The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis
por: Hemond, Christopher C., et al.
Publicado: (2019)

Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity
por: Bose, Gauruv, et al.
Publicado: (2023)

Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability
por: Sotiropoulos, Marinos G, et al.
Publicado: (2021)

Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis
por: Healy, Brian C, et al.
Publicado: (2021)

History of fatigue in multiple sclerosis is associated with grey matter atrophy
por: Palotai, Miklos, et al.
Publicado: (2019)

A Pilot Study to Assess At-Home Speed of Processing Training for Individuals with Multiple Sclerosis
por: Barker, Lindsay, et al.
Publicado: (2019)

No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50
por: Bove, Riley, et al.
Publicado: (2013)

Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2017)

Serum neurofilament levels and patient‐reported outcomes in multiple sclerosis
por: Galetta, Kristin, et al.
Publicado: (2021)

Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis
por: Tauhid, Shahamat, et al.
Publicado: (2015)

Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
por: Regev, Keren, et al.
Publicado: (2016)

A Putative Alzheimer's Disease Risk Allele in PCK1 Influences Brain Atrophy in Multiple Sclerosis
por: Xia, Zongqi, et al.
Publicado: (2010)

Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients
por: Rosso, Mattia, et al.
Publicado: (2019)

The Role of CD4 T Cells in the Pathogenesis of Multiple Sclerosis
por: Chitnis, Tanuja
Publicado: (2007)

Effect of vitamin D on MS activity by disease-modifying therapy class
por: Rotstein, Dalia L., et al.
Publicado: (2015)

Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2020)

Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis
por: Dastagir, Akram, et al.
Publicado: (2018)

An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2
por: Bakshi, Rohit, et al.
Publicado: (2014)

Organizational- and system-level characteristics that influence implementation of shared decision-making and strategies to address them — a scoping review
por: Scholl, Isabelle, et al.
Publicado: (2018)

Exploration of machine learning techniques in predicting multiple sclerosis disease course
por: Zhao, Yijun, et al.
Publicado: (2017)

Preventing Multiple Sclerosis: The Pediatric Perspective
por: Hardy, Duriel, et al.
Publicado: (2022)

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
por: Chitnis, Tanuja, et al.
Publicado: (2018)

COVID-19 severity is associated with worsened neurological outcomes in multiple sclerosis and related disorders
por: Conway, Sarah E., et al.
Publicado: (2022)

Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity
por: Zhang, Tingting, et al.
Publicado: (2020)

The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis
por: Yousuf, Fawad, et al.
Publicado: (2016)

Strengthening referral of sick children from the private health sector and its impact on referral uptake in Uganda: a cluster randomized controlled trial protocol
por: Buregyeya, Esther, et al.
Publicado: (2016)

Factors associated with willingness to participate in a vaccine clinical trial among elderly Hispanic patients
por: Rikin, Sharon, et al.
Publicado: (2017)

Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

The Effect of Fingolimod on Conversion of Acute Gadolinium‐Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis
por: Oommen, Vinit V., et al.
Publicado: (2015)

Symptom Interconnectivity in Multiple Sclerosis: A Narrative Review of Potential Underlying Biological Disease Processes
por: Chitnis, Tanuja, et al.
Publicado: (2022)

Alterations of the human gut microbiome in multiple sclerosis
por: Jangi, Sushrut, et al.
Publicado: (2016)

Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis
por: Rosso, Mattia, et al.
Publicado: (2020)

Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis
por: Chu, Renxin, et al.
Publicado: (2016)

Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models
por: Chua, Alicia S., et al.
Publicado: (2015)

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
por: Barro, Christian, et al.
Publicado: (2022)

Experience with long-term rituximab use in a multiple sclerosis clinic
por: Barra, Megan E, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9etbg5o12dflfkrrnmkppr01s9